Entopsis is a clinical-stage biotechnology company developing novel therapeutics for neurodegenerative diseases, with a primary focus on modulating the kynurenine pathway and targeting alpha-synuclein pathology. The company is headquartered in the United States and is advancing innovative approaches to address the underlying mechanisms of Parkinson's disease and other neurodegenerative disorders[1].
| Attribute | Details |
|---|---|
| Headquarters | United States |
| Founded | 2012 |
| Focus | Kynurenine pathway modulators, alpha-synuclein |
| Status | Clinical stage |
Entopsis's lead approach targets the kynurenine pathway, a major route of tryptophan metabolism in the immune system and brain. This pathway generates several neuroactive metabolites that can be:
Therapeutic Approach:
The company also develops therapies targeting alpha-synuclein aggregation, a key pathological feature of Parkinson's disease.
ENT-01 is Entopsis's lead clinical candidate.
| Property | Description |
|---|---|
| Type | Small molecule |
| Mechanism | Kynurenine pathway modulator |
| Indication | Parkinson's Disease |
| Phase | Phase 2 |
| Status | Clinical development |
Development Highlights:
Clinical Development:
Entopsis has earlier-stage programs targeting:
The kynurenine pathway is increasingly recognized as important in neurodegeneration.[2]:
Entopsis's R&D focus:
Entopsis competes with other companies targeting neuroinflammation:
| Year | Event |
|---|---|
| 2020s | Series funding rounds |
| 2012 | Company founded |
Entopsis's development priorities:
Entopsis. Company Website. 2024. ↩︎
Schwarcz R, et al. The kynurenine pathway in neurodegeneration. Neurobiology of Disease. 2014. ↩︎